%PDF-1.6
%
1 0 obj
<>
endobj
4 0 obj
<>stream
2020-11-05T20:37:09+05:30
2020-11-05T20:37:09+05:30
2020-11-05T20:37:09+05:30
Arbortext Advanced Print Publisher 9.0.114/W
application/pdf
AID-2020-0049-ver9-Ondoa-Suppl_4P 1..2
uuid:d611faf3-1583-4058-8d94-72537ab6083a
uuid:5a22c41f-3d84-49eb-8112-f086021a26c0
Acrobat Distiller 8.1.0 (Windows)
endstream
endobj
2 0 obj
<>
endobj
5 0 obj
<>
endobj
25 0 obj
<>stream
0 0 0 rg
/GS1 gs
62.022 649.701 239.131 .28345 re
f
62.022 373.153 239.131 .28345 re
f
62.022 611.149 239.131 .22681 re
f
BT
/F2 1 Tf
9.845 0 0 9.845 100.5165 725.1588 Tm
0 Tc
0 Tw
[(Supplementary)-334.7(Table)]TJ
/F3 1 Tf
10.279 0 TD
(S2.)Tj
/F2 1 Tf
1.8024 0 TD
(Estimates)Tj
-14.2121 -1.0135 TD
[(of)-337(the)-332.4(Cumulative)-336.5(Probability)-333(of)-331.2(Remaining)]TJ
.5643 -1.0135 TD
[(Virologically)-335.6(Suppressed)-335.2(After)-335.2(Initiating)]TJ
1.0193 -1.0077 TD
[(Antiretroviral)-332.4(Therapy)-338.3(or)-335.8(Switching)]TJ
-1.1632 -1.0135 TD
[(to)-335.8(a)-334.8(Second-)-330(or)-335.8(Third-Line)-337.2(Antiretroviral)]TJ
1.002 -1.0135 TD
[(Therapy)-332.6(Among)-335.8(Patients)-337(Participating)]TJ
-.4664 -1.0135 TD
[(to)-330(the)-332.4(Pan-African)-337.3(Studies)-336(to)-335.8(Evaluate)]TJ
2.6892 -1.0077 TD
[(Resistance)-334.2(Cohort)]TJ
/F3 1 Tf
8.9373 0 TD
(2007)Tj
/F2 1 Tf
1.9982 0 TD
()Tj
/F3 1 Tf
.501 0 TD
(2015)Tj
/F4 1 Tf
-16.861 -3.8697 TD
[(No.)-334.6(of)-336.2(months)]TJ
9.4498 2.027 TD
[(No.)-334.6(of)]TJ
-.9386 -1.0135 TD
(virological)Tj
.5068 -1.0135 TD
(failures)Tj
/F3 1 Tf
7.3837 0 0 6.5625 180.9637 621.751 Tm
(a)Tj
/F4 1 Tf
9.845 0 0 9.845 234.4818 637.2849 Tm
(Probability)Tj
-.3282 -1.0135 TD
[(of)-336.2(remaining)]TJ
-1.6873 -1.0135 TD
[(suppressed)-334(\(95%)-339(CI\))]TJ
/F3 1 Tf
-15.502 -1.8946 TD
[(After)-335.4(initiating)-334.6(rst-)-338.8(or)-330.2(second-line)-337.1(ART)-334.2(\()]TJ
/F4 1 Tf
17.4254 0 TD
(n)Tj
/F5 1 Tf
.668 0 TD
(=)Tj
/F3 1 Tf
.7198 0 TD
(2,420)Tj
-17.8227 -1.0135 TD
[(patients)-338.9(with)]TJ
/F5 1 Tf
5.5743 0 TD
()Tj
/F3 1 Tf
.5528 0 TD
[(2)-335(sVL)-333(results\))]TJ
-6.1156 -1.0135 TD
[(12)-8467(81)-4960.1(0.97)-334.6(\(0.960.97\))]TJ
0 -1.0077 TD
[(24)-7966(269)-4961.1(0.88)-334.6(\(0.870.90\))]TJ
0 -1.0135 TD
[(36)-7966(348)-4961.1(0.83)-334.6(\(0.810.84\))]TJ
T*
[(48)-7966(370)-4961.1(0.80)-334.6(\(0.780.82\))]TJ
T*
[(60)-7966(396)-4961.1(0.78)-334.6(\(0.750.80\))]TJ
0 -1.0077 TD
[(72)-7966(414)-4961.1(0.74)-334.6(\(0.720.77\))]TJ
-1.002 -1.0135 TD
[(After)-335.4(switch)-336.4(to)-336.2(second-)-331.6(or)-336(third-line)-334.3(ART)]TJ
.9905 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F5 1 Tf
.668 0 TD
(=)Tj
/F3 1 Tf
.7198 0 TD
[(149)-331.2(switches\))]TJ
-1.7103 -1.0077 TD
[(12)-8962.3(8)-4964.9(0.92)-334.6(\(0.840.96\))]TJ
0 -1.0135 TD
[(24)-8467(17)-4960.1(0.79)-334.6(\(0.690.87\))]TJ
T*
[(36)-8467(20)-4960.1(0.73)-334.6(\(0.600.82\))]TJ
T*
[(48)-8467(23)-4960.1(0.60)-334.6(\(0.420.74\))]TJ
0 -1.0077 TD
[(60)-8467(24)-4960.1(0.53)-334.6(\(0.330.70\))]TJ
-1.002 -1.0135 TD
[(After)-335.4(initiating)-334.6(rst-)-338.8(or)-330.2(second-line)-337.1(ART)-334.2(for)-337(those)]TJ
.9905 -1.0135 TD
[(with)-333.4(no)-336(change)-337.7(in)-330.4(regimen)-338.9(\()]TJ
/F4 1 Tf
11.7014 0 TD
(n)Tj
/F5 1 Tf
.6622 0 TD
(=)Tj
/F3 1 Tf
.7198 0 TD
[(2,271)-335.6(patients\))]TJ
-13.0719 -1.0135 TD
[(12)-8467(42)-4960.1(0.98)-334.6(\(0.970.99\))]TJ
0 -1.0077 TD
[(24)-7966(179)-4961.1(0.92)-334.6(\(0.900.93\))]TJ
0 -1.0135 TD
[(36)-7966(244)-4961.1(0.87)-334.6(\(0.850.88\))]TJ
T*
[(48)-7966(264)-4961.1(0.84)-334.6(\(0.830.86\))]TJ
0 -1.0077 TD
[(60)-7966(282)-4961.1(0.82)-334.6(\(0.800.84\))]TJ
0 -1.0135 TD
[(72)-7966(299)-4961.1(0.79)-334.6(\(0.770.82\))]TJ
6.5633 0 0 5.8334 70.0157 365.2723 Tm
(a)Tj
8.7511 0 0 8.7511 72.9637 361.3605 Tm
[(As)-328.7(dened)-338.5(by)-328.1(study)-334.7(VL.)]TJ
-.3369 -1.0236 TD
[(ART,)-362.8(antiretroviral)-365.3(therapy;)-364.8(CI,)-364.1(condence)-369.8(interval;)-361.1(sVL,)-365.2(study)]TJ
-.9134 -1.0236 TD
[(viral)-334.7(load.)]TJ
ET
313.058 679.634 239.131 .22681 re
f
313.058 345.316 239.131 .22678 re
f
387.439 650.778 164.75 .22675 re
f
313.058 633.09 239.131 .22681 re
f
BT
/F2 1 Tf
9.845 0 0 9.845 323.9432 725.1588 Tm
[(Supplementary)-334.7(Table)]TJ
/F3 1 Tf
10.279 0 TD
(S3.)Tj
/F2 1 Tf
1.8024 0 TD
[(Cumulative)-336.5(Acquired)]TJ
-9.8183 -1.0135 TD
[(HIV)-338.6(Drug)-334(Resistance)-334.2(After)-335.2(Initiating)]TJ
-1.4569 -1.0135 TD
[(Antiretroviral)-338.1(Therapy,)-330.2(by)-335.8(Follow-Up)-334(Time)]TJ
-1.3014 -1.0077 TD
[(Among)-330.1(Patients)-325.5(Participating)-331.7(to)-324.3(the)-332.4(Pan-African)]TJ
0 -1.0135 TD
[(Studies)-295.7(to)-295.5(Evaluate)-297.6(Resistance)-299.6(Cohort)]TJ
/F3 1 Tf
18.5713 0 TD
(2007)Tj
/F2 1 Tf
1.9982 0 TD
()Tj
/F3 1 Tf
.501 0 TD
(2015)Tj
/F4 1 Tf
-11.638 -1.8427 TD
[(Patients)-333.1(with)]TJ
/F5 1 Tf
5.6894 0 TD
()Tj
/F4 1 Tf
.5528 0 TD
[(2)-329.2(consecutive)]TJ
-5.0675 -1.0135 TD
[(sVL)-337.8(results)-336.2(\()]TJ
/F3 1 Tf
5.223 0 TD
(N)Tj
/F5 1 Tf
.8811 0 TD
(=)Tj
/F4 1 Tf
.7198 0 TD
(2,420\))Tj
-10.4863 -1.8139 TD
(Total)Tj
/F3 1 Tf
7.3837 0 0 6.5625 408.2456 643.6912 Tm
(b)Tj
9.845 0 0 9.845 447.0802 639.3258 Tm
(n)Tj
/F4 1 Tf
.8292 0 TD
[(\(%\))-3568.5(No)-331.2(VL)-337(data)]TJ
/F3 1 Tf
-14.4424 -1.9003 TD
[(HIV)-338.6(drug)-332.2(resistance)]TJ
7.3837 0 0 6.5625 394.0723 625.0392 Tm
(a)Tj
9.845 0 0 9.845 400.7054 620.6172 Tm
[(\(NRTI,)-333.8(NNRTI,)-334.6(or)-336(PI\))]TJ
-7.9007 -1.0077 TD
[(01)-331.2(years)-2730.9(2,420)-3226.4(54)-336(\(2.2\))]TJ
/F4 1 Tf
21.5197 0 TD
(0)Tj
/F3 1 Tf
-21.5197 -1.0135 TD
[(12)-331.2(years)-2730.9(2,313)-2725.4(139)-337(\(6.0\))]TJ
/F4 1 Tf
20.5234 0 TD
(107)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(23)-331.2(years)-2730.9(1,638)-2725.4(129)-337(\(7.9\))]TJ
/F4 1 Tf
20.5234 0 TD
(782)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(34)-331.2(years)-3105.2(883)-3602.1(83)-336(\(9.4\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,537)Tj
/F3 1 Tf
-19.7748 -1.0077 TD
[(45)-331.2(years)-3105.2(818)-3602.1(86)-336(\(10.5\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,602)Tj
/F5 1 Tf
-19.7748 -1.0135 TD
(>)Tj
/F3 1 Tf
.5528 0 TD
[(5)-335(years)-3548.6(579)-3602.1(72)-336(\(12.4\))]TJ
/F4 1 Tf
19.222 0 TD
(1,841)Tj
/F3 1 Tf
-20.7768 -1.0135 TD
[(NRTI)-340.9(drug)-332.2(resistance)]TJ
1.002 -1.0077 TD
[(01)-331.2(years)-2730.9(2,420)-3226.4(49)-336(\(2.0\))]TJ
/F4 1 Tf
21.5197 0 TD
(0)Tj
/F3 1 Tf
-21.5197 -1.0135 TD
[(12)-331.2(years)-2730.9(2,313)-2725.4(118)-337(\(5.1\))]TJ
/F4 1 Tf
20.5234 0 TD
(107)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(23)-331.2(years)-2730.9(1,638)-2725.4(110)-337(\(6.7\))]TJ
/F4 1 Tf
20.5234 0 TD
(782)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(34)-331.2(years)-3105.2(883)-3602.1(74)-336(\(8.4\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,537)Tj
/F3 1 Tf
-19.7748 -1.0077 TD
[(45)-331.2(years)-3105.2(818)-3602.1(76)-336(\(9.3\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,602)Tj
/F5 1 Tf
-19.7748 -1.0135 TD
(>)Tj
/F3 1 Tf
.5528 0 TD
[(5)-335(years)-3548.6(579)-3602.1(64)-336(\(11.1\))]TJ
/F4 1 Tf
19.222 0 TD
(1,841)Tj
/F3 1 Tf
-20.7768 -1.0135 TD
[(NNRTI)-337(drug)-338(resistance)]TJ
1.002 -1.0135 TD
[(01)-331.2(years)-2730.9(2,420)-3226.4(51)-336(\(2.1\))]TJ
/F4 1 Tf
21.5197 0 TD
(0)Tj
/F3 1 Tf
-21.5197 -1.0077 TD
[(12)-331.2(years)-2730.9(2,313)-2725.4(131)-337(\(5.7\))]TJ
/F4 1 Tf
20.5234 0 TD
(107)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(23)-331.2(years)-2730.9(1,638)-2725.4(124)-337(\(7.6\))]TJ
/F4 1 Tf
20.5234 0 TD
(782)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(34)-331.2(years)-3105.2(883)-3602.1(77)-336(\(8.7\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,537)Tj
/F3 1 Tf
-19.7748 -1.0135 TD
[(45)-331.2(years)-3105.2(818)-3602.1(83)-336(\(10.1\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,602)Tj
/F5 1 Tf
-19.7748 -1.0077 TD
(>)Tj
/F3 1 Tf
.5528 0 TD
[(5)-335(years)-3548.6(579)-3602.1(69)-336(\(11.9\))]TJ
/F4 1 Tf
19.222 0 TD
(1,841)Tj
/F3 1 Tf
-20.7768 -1.0135 TD
[(PI)-335.8(drug)-332.2(resistance)]TJ
1.002 -1.0135 TD
[(01)-331.2(years)-2730.9(2,420)-3727.3(1)-335(\(0.04\))]TJ
/F4 1 Tf
21.5197 0 TD
(0)Tj
/F3 1 Tf
-21.5197 -1.0077 TD
[(12)-331.2(years)-2730.9(2,313)-3727.3(5)-335(\(0.2\))]TJ
/F4 1 Tf
20.5234 0 TD
(107)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(23)-331.2(years)-2730.9(1,638)-3727.3(6)-335(\(0.4\))]TJ
/F4 1 Tf
20.5234 0 TD
(782)Tj
/F3 1 Tf
-20.5234 -1.0135 TD
[(34)-331.2(years)-3105.2(883)-4103.1(5)-335(\(0.6\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,537)Tj
/F3 1 Tf
-19.7748 -1.0135 TD
[(45)-331.2(years)-3105.2(818)-4103.1(4)-335(\(0.5\))]TJ
/F4 1 Tf
19.7748 0 TD
(1,602)Tj
/F5 1 Tf
-19.7748 -1.0077 TD
(>)Tj
/F3 1 Tf
.5528 0 TD
[(5)-335(years)-3548.6(579)-4103.1(3)-335(\(0.5\))]TJ
/F4 1 Tf
19.222 0 TD
(1,841)Tj
8.7511 0 0 8.7511 321.0519 333.5243 Tm
(Italic)Tj
/F3 1 Tf
2.5071 0 TD
[(gures)-379.7(represent)-382.5(the)-378.6(number)-379(of)-384.9(participants)-383.1(for)-375.9(whom)-383.9(no)]TJ
-3.4206 -1.0236 TD
[(sVL)-576.3(data)-573(were)-568.6(available)-573.5(and)-574.3(whom)-571.8(were)-568.6(not)-571.8(included)-573.6(in)-566.5(the)]TJ
0 -1.0301 TD
(analysis.)Tj
6.5633 0 0 5.8334 321.0519 310.507 Tm
(a)Tj
8.7511 0 0 8.7511 323.9999 306.5952 Tm
[(As)-335.2(dened)-332.1(by)-334.5(a)-330.4(study)-334.7(HIVDR)-332.4(genotyping)-330.4(results.)]TJ
6.5633 0 0 5.8334 321.0519 301.5495 Tm
(b)Tj
8.7511 0 0 8.7511 324.3401 297.6377 Tm
-.0148 Tc
[(N)-14.8(u)17.7(m)-14.8(b)15.9(er)-284.3(of)-277.8(patients)-277.6(s).9(t)-14.8(i)9.5(ll)-278(in)-285.7(follow-up)-279.3(w)-14.8(i)12.4(th)-279.2(at)-284.5(leas)-14.8(t)-268.7(t).6(w)-14.8(o)-267.4(con)5.8(s)-14.8(e)13.9(c)-1.8(utive)]TJ
-1.2892 -1.0236 TD
[(s)-14.9(V)12.7(L)-333.8(r).7(esults.)]TJ
.9135 -1.0236 TD
0 Tc
[(HIVDR,)-477.6(HIV)-479(drug)-473.3(resistance;)-475.8(NNRTI,)-477.9(non-nucleoside)-474(reverse)]TJ
-.9135 -1.0236 TD
[(transcriptase)-744.1(inhibitor;)-732.1(NRTI,)-735.9(nucleoside)-739.2(reverse)-735.9(transcriptase)]TJ
T*
[(inhibitor;)-336.9(PI,)-329.1(protease)-339.7(inhibitor.)]TJ
ET
endstream
endobj
22 0 obj
<>stream
8;Z\5>7SP)#i#;2aE=@P=\&fO2sI\@pg]:_0F$6*DpES7$NK>
d9ql=W(j+nq2lNG=ko;(2b@=`Z9]';Cn,UIF:ZJ73LhE@/4J=BL^9-oXeh!c9rlJs
3JIUqZR)10TeEPJni*0cj$%:^piB\H,@&V-R&aH#Q`rNm4H]@?ot,<'`g?B%Qc
GG2&FWb^U[Y*hRLqP:m!].c#CY*o"8_flUM<:p0Y(3tLI8PB3F3]DE?p2)M#?`Zop
7(7Ni@tndq6X=fY??Nd[l\%&ZE(T0[?$(Tqc!927r=Fu)(B`B,:+U9mO%2^AG\U$@
8[cM?jVA2W6D74('`J+$!<=:ZR&U~>
endstream
endobj
6 0 obj
<>/ProcSet[/PDF/Text]/ExtGState<>>>
endobj
7 0 obj
<>
endobj
19 0 obj
<>
endobj
16 0 obj
<>
endobj
13 0 obj
<>
endobj
8 0 obj
<>
endobj
11 0 obj
<>
endobj
10 0 obj
<>stream
hTP=o +<ީRĒSV͵;N "dȿ/4U,}gtD o#ꀳ[Bh,QqJU@_SgW=s+kt?>/6!@PEHa#`qRavD ?K8U,w
BiʍGV()isNcw>ʯ`
u
endstream
endobj
9 0 obj
<>
endobj
12 0 obj
<>stream
hbd`ad`ddpqt pvL){X_=Q$ W P̦dR]o*XOqALߏ?D,
<cZWpALߏEr!?Z~TG(@ U
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>stream
hdWiXSg9"P8Gω֕U*(,}M"!KD"`E\PkֺUGkvƯt'\3~|ߕzy9s?p縹lqyA{ӳ% Y!ĉ7\kT%]&7]5pِ'I1sb
W,?.8.%&
{db0[,I$APV l"X&ESP,HQB0;A)MJdyBAABN\ '>(NONOd7=>3p>pp88 gg9كq8l8V7n\75nrSf6NO/s\px/`USfO'yr{SwM<_GQ
_w`:ľg?Gfz3s`'#6mGηM$"QlR*UbS12V̯ɦc܂MZ)sS:74ωh˫G0z"SUh)+a ZOD[F6 v"/چAQ ݄fV;'x@ &' B־u\@SE>C+z͵䐨+]KF3Ȕ)E4_hso2ǔ-&bsfe
7<|V˳
aA?=v<H2(I09 w|1>lv]'רOϊ"bUL{]< HtzOTJ v3f7ͯc,O'l
[SD((5Vqrme[1Qh3?q>]_cȆr0%xh\:\4Kͻ
] vj|@W
TI⧈Gޟ=E4ꕴҠҩzQCNTGG>CyL6D;pa|W8(- gL|=z _8F͌h|-֢OYm [6rޚe>a˗G훣WݛOfn'
.
RA, sVݝoE#ϛ[7Еƒx4
EmY~@?YdB<,Q2GEa|m--jo>
+@m,:ˀa;{YeRIezZq?003^:VW_q
R]Yq$
&Q<_3,&zFQsx6D'{3)6c
)fU4m/2װhn9<@Z_+o0{
q:A4Cz hB
~7AVZQ0(DeT#k}@"Kyb۵|@&wHaH#e:q0;h"\,RԮGʽ[UҀSӉM7X,~˜dR-dp`h?chQ4 e)ȧ4\S@cN5v<\K cem&9M)4I+є5[RQ0#Mac
(0cPwuUMBϴlMJ#XHpYZ#UՅLL\K-\m?ӛv̍R+h~t6VͥUKZΉ;|qd߱CUG)+܉XHIiʪ_:Fk q4dSXv"˒^v8bPA )7ݽJ{ڈ/ &wuFϝfe4]._J,RS{aڡ,uĕjTE\M7bzX\ol
YA+v
B?Y#Jk#)~
y/a49uJF,'%vU[nr4,Wcq"t! R*TXX;u~~;Z&GKF^ۻumG"Z= ;Ҥ%F|Ʃ[C4|>X~pj;TXѡ(1"12!=Jh:-Lg%!9ud?#}ҳ_tO\d|9GX[SLd[~N5@ɢn
x`xu2wqs1UHaJJMɒ&өـމDӋp+5ŵjMd"["x!qId:5<<`p)
QYoS,kfFq?EDF(VS>l9QEռNU71~y,N+5A{N21!L&,)T1-G8P}0`ZEx:OmzkI"$F}l6'F)G})
Dd^jpbwbRkk*p`N֮Pl]UĐ2SK?;AwayoXR*out;'7U+ښyp#) o. s+38q9Vxe#,
F#$+ &90,h.Ee.Ad_ix)x` S3we7nF kv>l':FHנ